# Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

> **NCT06686108** · PHASE2 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 59 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Relapse

## Interventions

- **DRUG:** Azacitidine (AZA) Days 1 - 5
- **DRUG:** Decitabine (DAC)
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06686108
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2027-10-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06686108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06686108, "Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06686108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*